Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 19;10:2972. doi: 10.3389/fimmu.2019.02972

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Vian, Le, Gazaniga, Kieltyka, Liu, Pietropaolo, Dell'Orso, Brooks, Furumoto, Thomas, O'Shea, Sciumè and Gadina.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Impact of tofacitinib treatment on the functions of NK cells and ILC1. (A) Bar graphs show the percentage of IFN-γ-positive ILC1 and NK cells, quantified by flow cytometry, after 2 h stimulation with PMA/Ionomycin (P/I), or 6 h stimulation with IL-2/IL-12 or IL-12/IL-18, in mice treated or not for 1 week with tofacitinib. Two experiments were combined. (B) Percentage of Ki67-positive ILC1 and NK cells isolated from liver after 7 days administration of tofacitinib or vehicle. (C) Representative histogram plots (left panel) and bar graphs (MFI, right panel) show Bcl2 protein expression in ILC1 and NK cells from mice treated with tofacitinib or vehicle. *P < 0.05; ***P < 0.001.